Dose‐response effects of zaleplon as compared with triazolam (0·25 mg) and placebo in chronic primary insomnia

Human Psychopharmacology - Tập 15 Số 8 - Trang 595-604 - 2000
Christopher L. Drake1, Timothy Roehrs1, Richard M. Mangano2, Thomas Roth1
1Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, MI 48202, USA
2Clinical Research and Development, Wyeth‐Ayerst Research, Radnor, PA, USA

Tóm tắt

Abstract

The effects of two nights of treatment with the short‐acting benzodiazepine receptor agonist zaleplon, triazolam, or placebo was assessed in chronic primary insomniacs using two concurrent, multi‐center, randomized, double‐blind, Latin Square crossover studies. Study 1 (n = 47) compared zaleplon (10 and 40 mg) to triazolam (0·25 mg) and placebo. Study 2 (n = 36) compared zaleplon (20 and 60 mg) to triazolam (0·25 mg) and placebo. For each study, polysomnographically recorded sleep parameters and patient reports of sleep quality were collected during baseline and two consecutive nights during the four treatment phases in each study. All doses of zaleplon produced significant decreases in latency to persistent sleep. Although no minimally effective dose could be determined, dose‐response effects were apparent. Triazolam 0·25 mg produced a decrease in latency to persistent sleep that was comparable to that of zaleplon 10 mg. Only the triazolam dose and the 60 mg dose of zaleplon produced significant increases in total sleep time over placebo. Zaleplon 40 and 60 mg and triazolam produced decreases in the percentage of REM sleep compared to placebo. Patient reports of efficacy were consistent with objective findings. In addition, all doses of zaleplon tended to increase while triazolam decreased the percentage of stage 3/4 sleep. There was no evidence of residual daytime impairment for any of the zaleplon doses, however, triazolam administration produced significant impairment in performance on a digit copying test. A higher number of adverse events were seen with the 40 and 60 mg doses of zaleplon compared to triazolam (0·25) and placebo. At higher doses, zaleplon is more effective than triazolam at reducing latency to persistent sleep in chronic insomnia and is not associated with the decrease in slow‐wave sleep or residual impairment observed with triazolam. However, increases in total sleep time were apparent only at doses which produced concomitant increases in the number of adverse events. In contrast, triazolam (0·25 mg) produced increases in total sleep time (˜25 min) and decreases in latency to persistent sleep at a dose of 0·25 mg. Copyright © 2000 John Wiley & Sons, Ltd.

Từ khóa


Tài liệu tham khảo

10.1007/BF00265947

Ancoli‐Israel S, 1984, Effects of a single dose of flurazepam on the sleep of healthy volunteers, Arzneimittelforschung, 34, 99

Ancoli‐Israel S, 1999, Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I [In Process Citation], Sleep, 22, S347

American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders

10.1002/j.1552-4604.1994.tb02002.x

10.1007/BF00432435

10.1016/0091-3057(88)90212-2

10.1093/sleep/19.5.412

10.1046/j.1365-2125.1999.00024.x

Dement W, 1982, Daytime alertness, insomnia, and benzodiazepines, Sleep, 5, S28, 10.1093/sleep/5.suppl_1.S28

Dietrich B, 1995, Zaleplon: dose‐response evaluation in primary insomnia, Sleep Res, 24, 116

10.4088/JCP.v60n0806

10.1001/jama.1989.03430110069030

Hauri PJ, 1997, Cognitive deficits in insomnia patients, Acta Neurol Belg, 97, 113

10.1007/BF00426461

10.1056/NEJM199701303360506

10.1007/BF02599573

Mattmann P, 1982, Day‐time residual effects and motor activity after three benzodiazepine hypnotics, Arzneimittelforschung, 32, 461

Mitler MM, 2000, Nonselective and selective benzodiazepine receptor agonists—where are we today?, Sleep, 23, S39

Nowell PD, 1997, Benzodiazepines and zolpidem for chronic insomnia: a meta‐analysis of treatment efficacy, JAMA, 278, 2170, 10.1001/jama.1997.03550240060035

Rechtschaffen A, 1968, A Manual of Standardized Terminology, Techniques, and Scoring Systems for Sleep Stages of Human Subjects

10.1007/BF02245054

10.1002/(SICI)1099-081X(199904)20:3<171::AID-BDD169>3.0.CO;2-K

Roth T, 1999, Dynamic consequences and correlates of insomnia in the United States: results of the 1991 National Foundation Survey. II [In Process Citation], Sleep, 22, S354

Roth T, 1980, The differential effects of short‐ and long‐acting benzodiazepines upon nocturnal sleep and daytime performance, Arzneimittelforschung, 30, 891

10.1111/j.1365-2125.1979.tb00456.x

10.1016/S0091-6749(87)80197-5

10.1093/sleep/18.4.246

Roth T, 1991, A review of the safety profiles of benzodiazepine hypnotics, J Clin Psychiatry, 52, 38

10.1002/j.1875-9114.1983.tb03237.x

Scharf MB, 1994, A multicenter, placebo‐controlled study evaluating zolpidem in the treatment of chronic insomnia, J Clin Psychiatry, 55, 192

10.1176/ajp.154.10.1417

Spitzer RL, 1987, Diagnostic and Statistical Manual of Mental Disorders

10.2165/00044011-199816050-00001

10.1016/S0163-8343(97)00056-X

Thông tin
Thông tin xuất bản

Human Psychopharmacology

Tập 15 Số 8

595-604

Thông tin tác giả